Non-Hodgkin Lymphoma (NHL) Market is Expected to Register a Considerable Growth by 2026

The report entitled; “Non-Hodgkin Lymphoma (NHL) Market, Trends, Dynamics, and Market Analysis,” recently published by Stratview Research offers a comprehensive outlook of the industry. This report by Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, Others), Application (Hospital, Clinic), and Region – COVID-19 Impact Analysis and Forecast to 2026.

The market is bifurcated into various segments. Below given is the segment-wise analysis –

By type, the non-Hodgkin lymphoma (NHL) market has been bifurcated into hospitals and clinics. Under these, the hospital segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment growth can be attributed to the presence of established infrastructure and skilled healthcare staff.

By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The segment growth is primarily attributed to the rising number of people suffering from lymphoma cancer coupled with the presence of key market players such as Bristol Myers Squibb (US) and Celgene Corporation (US). The market growth in the Asia-Pacific region is expected to be driven by the increasing prevalence of cancer disease.

Who are the Key Players in the Market?

This report provides market intelligence in the most comprehensive way. It also provides critical insights into the key players active in the market, that will enable strategic decision-making for the existing market players as well as those willing to enter the market. The following are the key players active in the Non-Hodgkin Lymphoma (NHL) Market:

  • F. Hoffmann-La Roche AG (Switzerland)
  • Johnson & Johnson (US)
  • The Merck Group (Germany)
  • Bristol Myers Squibb (US)
  • Celgene Corporation (US)
  • Eli Lilly and Company (US)
  • GlaxoSmithKline plc (UK)
  • Bayer AG (Germany)
  • AstraZeneca plc (UK)
  • The Takeda Pharmaceutical Company Limited (Japan).

Key questions answered by the report

  • What is the projected CAGR for revenue from the Non-Hodgkin Lymphoma (NHL) Market during the forecast period?
  • What would be the market be valued at by 2027?
  • What is a major driving factor for growth of the market?
  • Which region accounted for largest revenue share in the Non-Hodgkin Lymphoma (NHL) Market?
  • Which are the major market players?

Custom Research:

Stratview research delivers custom research services across the sectors. In case of any custom research requirements, please send your inquiry to [email protected] Or connect with our experts at +1-313-307-4176.

About Us

Stratview Research is a global market research firm, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with insightful market data to aid strategic decision making. These exclusive reports are the result of exclusive research methodology and are available for key industries such as chemicals, composites, advanced materials, technology, renewable energy, and more.

One thought on “Non-Hodgkin Lymphoma (NHL) Market is Expected to Register a Considerable Growth by 2026

Leave a Reply

Your email address will not be published.